{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Assessed using a correlated logistic regression model and generalized estimating equations (GEE). Covariates such as dose level and use of prophylactic cytokines may also be included in this model. A Wilcoxon test will be used to assess the equality of the distributions of the continuous levels of predicted tumor radiation from the In2B8 scans by response.","groups":[{"description":"Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.\n\nrituximab: Given IV\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV\n\nindium In 111 ibritumomab tiuxetan: Given IV\n\noprelvekin: Given subcutaneously\n\nfilgrastim: Given subcutaneously","id":"OG000","title":"Treatment (Radiolabeled Monoclonal Antibody Therapy)"}],"populationDescription":"Not collected. Study team decision not to analyze this endpoint.","reportingStatus":"POSTED","timeFrame":"At week 12","title":"Association Between the Amounts of Tumor Radiation Indicated by the In2B8 Scan and Tumor Response (Phase I)","type":"SECONDARY"}